ArticleCureus2020

Third Line Eribulin for Triple-negative Metastatic Breast Ductal Carcinoma Resulting in Extended Progression-free Survival of 57 Months.

Sukesh Manthri et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.